BACKGROUND Production of tissue Plasminogen Activator protein (t-PA) in prokaryotes systems has many problems such as the lack of active protein production, multiple purification steps, and renaturation process which has been shown to be costly and time-consuming. METHODS In this study, reteplase which is the nonglycosylated active domain of t-PA was used to transform TOP10 Escherichia coli (...

BACKGROUND Reteplase (recombinant plasminogen activator), a mutant of alteplase tissue plasminogen activator, has a longer half-life than its parent molecule and produced superior angiographic results in pilot studies of acute myocardial infarction. In this large clinical trial, we compared the efficacy and safety of these two thrombolytic agents. METHODS A total of 15,059 patients from 807 h...

background: production of tissue plasminogen activator protein (t-pa) in prokaryotes systems has many problems such as the lack of active protein production, multiple purification steps, and renaturation process which has been shown to be costly and time-consuming. methods: in this study, reteplase which is the nonglycosylated active domain of t-pa was used to transform top10 escherichia coli (...

ALI = acute limb ischemia, APSAC = antistreplase, MTD = mechanical thromboembolectomy device, PAT = percutaneous aspiration thromboembolectomy, pro-UK = prourokinase, RPA = reteplase, r-UK = recombinant urokinase, SK = streptokinase, STILE = Surgery versus Thrombolysis for Ischemia of the Lower Extremity [study], tPA = tissue plasminogen activator, TOPAS = Thrombolysis or Peripheral Arterial Su...

PURPOSE To compare the efficacy, safety, and costs associated with catheter-directed thrombolysis with urokinase (UK) and the recombinant agents alteplase (tissue plasminogen activator [TPA]) and reteplase (recombinant plasminogen activator [RPA]) in the treatment of symptomatic deep vein thrombosis (DVT). MATERIALS AND METHODS The authors conducted a retrospective analysis on 74 patients (82...

Abbreviations: APTT 5 activated partial thromboplastin time; ASSENT 5 Asessment of the Safety and Efficacy of a New Thrombolytic Agent; CI 5 confidence interval; FTT 5 Fibrinolytic Therapy Trialists’ Collaborative Group; GISSI 5 Gruppo Italiano per lo Studio Streptokinasi nell’Infarto Miocardico; GP 5 glycoprotein; GUSTO 5 Global Utilization of Streptokinase and TPA (alteplase) for Occluded Cor...

Aims Abciximab has previously been shown to enhance thrombolysis and improve myocardial perfusion when combined with reduced doses of alteplase. The purpose of the reteplase phase of TIMI 14 was to evaluate the effects of abciximab when used in combination with a reduced dose of reteplase for ST-elevation myocardial infarction. Methods and Results Patients (n=299) with ST-elevation myocardial i...

Reteplase is a potent thrombolytic agent which is widely used in the management of acute myocardial infarction and stroke. It belongs to the third generation of the thrombolytic drugs and has been derived from native human tissue plasminogen activator by removing three domains of it and keeping the Kringle 2 and Serine protease domains. However, the high cost of this drug, has limited the appli...

BACKGROUND Plasminogen activator therapy for acute myocardial infarction is limited by lack of achievement of early, complete, and sustained reperfusion in a substantial proportion of patients. Many phase II trials have supported the potential of combined fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition for improving reperfusion. We did a randomised, open-label trial to compar...

BACKGROUND Changes in platelet aggregation (PA) and platelet surface receptor expression induced by thrombolytic therapy for acute myocardial infarction may influence the rate of initial reperfusion and early reocclusion. METHODS AND RESULTS In the RAPID-1 (Reteplase Angiographic Phase II International Dose-finding study), RAPID-2 (Reteplase vs Alteplase Patency Investigation During myocardia...